Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Bulbo-Spinal Atrophy, X-Linked × abiraterone × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 5 Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Primary Myelofibrosis 1 Pancreatic Neoplasms 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia 1 Glioblastoma 1 Genital Neoplasms, Male 1 Genital Diseases, Male 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Castration-resistant Prostate Cancer 1 Carcinoma, Hepatocellular 1

Interventions

enzalutamide 1 darolutamide 1 abiraterone 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07190300 2026-03-02

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting

Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡